HCPCS G9913: HBV Status Not Assessed Before Anti-TNF Initiation - OpenPayer

Summary & Overview

HCPCS G9913: HBV Status Not Assessed Before Anti-TNF Initiation

HCPCS Level II code G9913 documents that Hepatitis B virus (HBV) status was not assessed and results were interpreted prior to initiating anti-TNF therapy, with the reason recorded as not otherwise specified. Nationally, accurate documentation of HBV screening before starting immunosuppressive biologics like anti-TNF agents is a patient-safety and utilization-management concern; G9913 flags cases where that assessment did not occur or could not be documented.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context, common billing scenarios, and what is typically included in service lines tied to pre-treatment infectious disease evaluation. The publication outlines where this code fits within outpatient and infusion-related workflows and highlights reporting implications for clinical teams and revenue cycle professionals.

This brief also summarizes expected benchmarks and policy considerations relevant to national payers, points to potential documentation gaps that prompt use of the code, and identifies areas where further coding detail or auxiliary claims elements (not provided here) typically support coverage determination. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9913HCPCS Level IIhepatitis banti-TNFpre-treatment screeninginfusion clinicoutpatient evaluationinfectious disease screening

Billing Code Overview

HCPCS Level II code G9913 indicates that Hepatitis B virus (HBV) status was not assessed and results were interpreted prior to initiating anti-TNF (tumor necrosis factor) therapy, with the reason categorized as not otherwise specified. This code documents that HBV evaluation was not completed before starting anti-TNF treatment and captures the clinical circumstance for the patient encounter.

Service type: Pre-treatment infectious disease screening / evaluation related to immunomodulatory therapy

Typical site of service: Outpatient clinic or infusion/infusion-preparation setting where initiation of anti-TNF therapy is assessed or administered

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 52-year-old patient with moderate to severe rheumatoid arthritis is being evaluated prior to initiation of anti-TNF biologic therapy. The clinician documents that hepatitis B virus testing was not performed and HBV status was not assessed before starting anti-TNF therapy, and a reason not otherwise specified is recorded (for example, patient refusal, pending laboratory access, or an urgent need to begin therapy). The typical clinical workflow includes pre-treatment counseling, review of infectious disease screening checklist, ordering of HBV surface antigen, core antibody, and surface antibody tests, and documentation of results and interpretation. In this scenario, the clinician documents absence of assessment and interprets prior results as unavailable, then bills using G9913 to indicate HBV status not assessed and results interpreted prior to initiating anti‑TNF therapy.

Typical site of service: outpatient infusion center, rheumatology or gastroenterology clinic, or hospital outpatient department where biologic therapy is initiated.

Typical patient scenario: patient requires prompt initiation of a TNF inhibitor for active autoimmune disease; laboratory testing could not be completed prior to dosing due to logistical reasons or patient factors; clinician documents reason and proceeds with treatment while noting HBV status not assessed and interpreted prior to anti‑TNF initiation.

Coding Specifications

Modifier	Description	When to Use

HCPCS G9176: Speech-Language Pathology Functional Limitation at Discharge

HCPCS-G6054-METHSUXIMIDE-ANTICONVULSANT-MEDICATION

HCPCS G6054: Methsuximide, Anticonvulsant Medication

HCPCS-G9920-SCREENING-NEGATIVE-RESULT

HCPCS Level II G9920: Screening Performed, Negative

HCPCS-G0568-INITIAL-PSYCHIATRIC-COLLABORATIVE-CARE-MANAGEMENT

HCPCS G0568: Initial Psychiatric Collaborative Care Management

HCPCS-G9352-MULTIPLE-CT-PARANASAL-SINUSES-REPEAT-WITHIN-90-DAYS

HCPCS G9352: Multiple CTs of Paranasal Sinuses Within 90 Days

HCPCS-G9537-IMAGING-CLINICAL-TRIAL-OR-EXTERNAL-ORDER

HCPCS G9537: Imaging for Clinical Trial or Externally Ordered Study

HCPCS-G9223-PJP-PROPHYLAXIS-LOW-CD4

HCPCS G9223: PJP Prophylaxis for Low CD4 Count

HCPCS-G9787-PATIENT-ALIVE-MEASUREMENT-YEAR-STATUS

HCPCS G9787: Patient Alive as of Measurement Year End

HCPCS-G9848-NO-SYSTEMIC-CANCER-THERAPY-LAST-14-DAYS-OF-LIFE

HCPCS G9848: No Systemic Cancer-Directed Therapy in Last 14 Days of Life

HCPCS-G8780-DIET-PHYSICAL-ACTIVITY-COUNSELING

HCPCS G8780: Counseling for Diet and Physical Activity Performed

Showing 1–10 of 1996

22

Taxonomy Code	Specialty	Notes
`207R00000X`	Rheumatology	Primary specialty initiating anti‑TNF therapy and performing pre‑treatment screening.
`207L00000X`	Gastroenterology	Initiates anti‑TNF therapy for inflammatory bowel disease and is responsible for HBV screening.
`207K00000X`	Allergy & Immunology	Manages biologic therapy for immune‑mediated disease and assesses infectious risk.
`208000000X`	Family Medicine	May initiate or coordinate pre‑treatment screening in outpatient settings.
`208D00000X`	Internal Medicine	Common provider for chronic disease management and pre‑biologic screening.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`M06.9`	Rheumatoid arthritis, unspecified	Common indication for anti‑TNF therapy; necessitates HBV screening prior to biologic initiation.
`K50.90`	Crohn's disease, unspecified, without complications	Inflammatory bowel disease commonly treated with anti‑TNF agents; HBV screening is standard prior to therapy.
`K51.90`	Ulcerative colitis, unspecified, without complications	Another IBD indication for anti‑TNF therapy requiring pre‑treatment infectious screening.
`L40.0`	Psoriasis vulgaris	Moderate to severe psoriasis may be treated with anti‑TNF biologics; HBV status assessment is recommended prior to therapy.
`M32.9`	Systemic lupus erythematosus, unspecified	Autoimmune disease where biologic agents are sometimes used; HBV screening is relevant before initiation.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80074`	Hepatitis B serology panel (includes HBsAg, anti‑HBs, anti‑HBc)	Laboratory testing commonly ordered before anti‑TNF initiation; would normally provide HBV status that `G9913` indicates was not assessed.
`36415`	Collection of venous blood by venipuncture	Blood draw for HBV serology; commonly performed prior to biologic therapy.
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Administration of first dose of an anti‑TNF agent; may occur when HBV status was not assessed.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate	Example of counseling codes used if additional counseling about infectious risk was provided during pre‑treatment visit.
`99497`	Advance care planning including first 30 minutes	Used only if separate, extensive decision‑making about risks/benefits and documentation were performed and billed separately.

OpenPayer